Richard S. Finn, MD, on LEAP-002 Trial Findings on Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma: Clinical Implications

Posted: Friday, September 30, 2022

Richard S. Finn, MD, of the University of California, Los Angeles Geffen School of Medicine, discusses clinical implications of phase III findings from the LEAP-002 study of lenvatinib plus pembrolizumab vs lenvatinib as first-line therapy for patients with advanced hepatocellular carcinoma.